Stocks · News reference

RBC Capital Maintains Outperform on Biogen, Raises Price Target to $260

Aug 25, 2026, 1:32 PMBenzinga Newsdesk

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $240 to $260.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 4, 2026, 8:00 AMBenzinga Newsdesk
Stoke, Biogen Report Lasting Seizure Reductions In Dravet Syndrome Study
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB) today announced presentations
BIIB STOK
BenzingaSep 3, 2026, 5:32 PMBenzinga Newsdesk
Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $245
BIIB
BenzingaSep 3, 2026, 8:06 AMBenzinga Newsdesk
Biogen And Eisai Win China Approval For At-Home Weekly Leqembi Alzheimer’s Treatment
Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB) announced today that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (subcutaneous autoinjector: SC-AI), the
BIIB
BenzingaSep 1, 2026, 11:31 AMBenzinga Newsdesk
Stoke Therapeutics, Biogen Present Data On Zorevunersen As Treatment For Dravet Syndrome At 16th European Epilepsy Congress
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced
BIIB STOK